ArticleJournal of managed care & specialty pharmacy2021

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.

Natalie J Engmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.